Latest News

Thayne Munce, PhD, discusses the challenges and unanswered questions shaping CTE research, as well as the implications of findings from former NFL players for athletes competing today.

uniQure submitted a BLA to FDA and an MAA to the UK's MHRA for ifezuntirgene inilparvovec, based on 3-year phase 1/2 data showing slowed Huntington disease progression.

The updated guideline offers evidence-graded recommendations on when to start migraine prevention, which medications to choose, and how to manage special populations.

The European Commission approved modified-release carbidopa/levodopa capsules, already available in the US as Crexont, for adults with moderate to severe motor fluctuations.

The randomized NATURE trial, presented as late-breaking science at ESC Congress 2026, showed that enVast-assisted thrombectomy reduced infarct size versus standard PCI in STEMI with large thrombus burden.

The chair of the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery discussed the major themes, clinical takeaways, and unanswered questions from the first update to the guideline in a decade.

New research examining the prevalence of chronic traumatic encephalopathy among former NFL players provides additional insight into CTE pathology, while highlighting the challenges of interpreting findings from postmortem brain-donation studies.

An analysis of more than 311,000 UK Biobank participants identified 13 pairs and 14 triplets of risk factors with significant additive interactions for late-onset Parkinson disease, with several potentially modifiable factors emerging as targets for prevention.

Lucy Morse, MD, a movement disorders specialist at Northwestern Medicine, discussed the push toward a biological definition for Parkinson disease, newly approved therapies, and why she believes referrals shouldn't wait.

Hannah Kopinsky, MD, an MS specialist at Northwestern Medicine, discussed recent updates to multiple sclerosis diagnostic criteria, the shift toward early high-efficacy treatment, and the unmet needs that remain in progressive MS.

A case report documented MOG-IgG antibodies in a mother's breast milk following severe MOGAD, though her breastfed infant's serum tested negative.

Phase 1b/2 findings showed that the investigational anti-amyloid monoclonal antibody ABBV-916 produced dose-dependent reductions in brain amyloid in adults with early Alzheimer disease, although development of the agent was discontinued before dose expansion because of sponsor business considerations.

In recognition of SMA Awareness Month, NeurologyLive® spoke with neuromuscular experts about how multidisciplinary care is built, where coordination breaks down, and what changes as patients live longer.